Outlook Therapeutics, Inc. - 10-Q Filing
Outlook Therapeutics filed its quarterly report on Form 10-Q for the quarter ended March 31, 2026. The filing includes financial data and disclosures related to equity incentive plans, convertible promissory notes issued in March 2025, a public offering conducted on March 25, 2026, and other debt instruments.
Tickers: $OTLK